TVAX Biomedical (TVAX) Files $40M IPO

TVAX Biomedical, Inc. (Nasdaq: TVAX), filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $40 million. TVAX plans to list on the Nasdaq Global Select market under the ticker, "TVAX."

The offering is being made through Roth Capital Partners, Cantor Fitzgerald & Co., and Morgan Joseph TriAtrisan.

TVAX is a biotechnology company focused on the development of targeted cell-based immunotherapies for the treatment of cancer.

---

Are you missing key trading opportunities? Upgrade to StreetInsider Premium and get a step ahead of the market - FREE TRIAL!